1º Author, Year | Type of cancer | Participants (N/Sex/Age) | Prevalence of dysphagia (N/%) | Diagnostic evaluation of dysphagia (How/Which) | Survival (mean or median/HR[CI]/rate) | Survival and dysphagia association (days/HR[CI]) |
---|---|---|---|---|---|---|
Liu et al., 2023 [26] | Lung cancer (NSCLC and SCLC) | 3634 (F = 1209, M = 2425); Mean age (SD): 60.2y (± 9.86) | 3% | Frequency during the hospital stay and 30 days after hospital admission (telephone follow-up): Patient-Generated Subjective Global Assessment* | Median = Non-NIS group: 20.6 months, NIS group: 31.2 months, p ≤ 0.001 | NIA days / 1.401 [1.07–1.81] |
Marmor et al., 2020 [25] | Lung cancer (NSCLC and SCLC) | 201.674 (F = 95.144, M = 106.530) Age: < 80y: 82% of N total | 8517 (4%) | Retrospective data: ICD-9-CM (diagnostic codes for dysphagia) and CPT | Median = with dysphagia: 8 months [95%CI 7–9] HR: 1.34 [95%CI 1.28–1.35] without dysphagia: 12 months [95%CI 11–13], p ≤ 0.0001 | NIA days / 1.34 [1.28–1.35] |
Abbas et al., 2019 [22] | Lung cancer (NSCLC) | 63 (F = 22, M = 41) Median age (interquartile range) = 66.6y (57.2–72.1) | 4 (7.1%) of 56 patients alive after 6 months | Frequency not reported: CTCAE version 3.0* | Median = 21 months | Not |
Markos et al., 2019 [21] | Lung cancer (NSCLC) | 42 (F = 7, M = 35) Mean age (range) = 68.4y (52–80) | All patients | Frequency not reported: cites the stages, but does not refer to which protocol | Mean = 4 months | Not |
Arscott et al., 2018 [23] | Melanoma Lung cancer (NSCLC) Kidney cancer Liver cancer Myeloma Sarcoma | 30 (F = 9, M = 21) Median age at time of RT (range) = 61y (27–82) | 9 (30%) | Frequency not reported: CTCAE version 4.0* | Median = 87 days | Not |
Kim et al., 2018 [24] | Lung cancer (NSCLC and SCLC) | 84 (F = 23, M = 61) Mean age (SD) = Stent group: 62.4y (± 11.5), Gastrostomy group: 58.5y (± 6.3) | All patients | Retrospective data: SEMS or PG placement | HR: 0.682 p = 0.219 (between SEMS and PG) | Not |
Hatton et al., 2016 [30] | Lung cancer (NSCLC) | 18 (F = 4, M = 14) Mean age (range) 70y (44–84) | 16% | Frequency not reported: CTCAE version 4.0* | Rate: 2 years of survival = 49% | Not |
Thier et al., 2016 [32] | Glioblastoma | 57 (F = 18, M = 39) Mean age at death (SD) = 59y (± 11) | 37 (65%) | Daily: Signs, symptoms, and treatment strategies were registered using the standardized protocol + additional information from the patients’ charts* | Mean = 48 weeks | Not |
Bradley et al., 2015 [28] | Lung cancer (NSCLC) | 465 (F = 188, M = 277) Median (range) = 60 Gy group: 64y (38–83), 74 Gy group: 64y (41–83), Cetuximab group: 64y (38–83), No-cetuximab group: 64y (37–82) | 139 (31%) | Frequency not reported: CTCAE version 3.0* | Median (months) 60 Gy group: 28.7 = 1.38 [1·09–1·76], 74 Gy group: 20.3, p = 0.004 | Cetuximab group: 25 = 1.07 [0.84–1.35], No-cetuximab group: 24.0, p = 0,29 | Not |
Koekkoek et al., 2014 [27] | Highgrade Glioma | 178 (F = 53, M = 125); Mean age at diagnosis, years (SD)—59.7 (12.5) | Dysphagia prevalence at 3 months before death = 7.5%, Dysphagia prevalence at 1 week before death = 24.5% | Physicians who had been involved in EOL care for these patients were invited to complete questionnaires on the EOL phase | Median = Group with grade IV—10.6 months [9.2–12.1], Group with grade III = 12.4 months [10.6–14.1], p ≥ .05 | Not |
Ansari et al., 2014 [31] | Thymoma | 45 (F = 18, M = 27) Mean age (range) = 43y (45.4 ± 17.7) | 3 (7%) | Every 3 months for the first 2 years Every 4 months during the third year Every 6 months in the fourth and fifth years and annually thereafter: history and physical examination* | Rate (5 years of survival = 70.8%, 10 years of survival = 62.9%) | Not |
Ediebah et al., 2014 [2] | Lung cancer (NSCLC) | 391 (F = 136, M = 255) Median age (range) = Group A: 57y (27–75), Group B: 57y (28–75), Group C: 56y (31–75) | 307 (78.5%) | Every 6 weeks: global health status/QOL scale* | Median = (F = 9.6 months, M = 7.2 months) | NIA days / 1.12 [1.04–1.20] |
Oberije et al., 2014 [33] | Lung cancer (NSCLC and SCLC) | 155 (F = 69, M = 86) Mean age (SD) = NSCLC group: 64.7y (± 10.5), SCLC group: 65.5y (± 8.8) | Grade ≥ 3 dysphagia = NSCLC group: 14 (11.6%), SCLC group: 3 (12.0%) | Any timepoint during or after the end of RT, with a maximum of 4 weeks: CTCAE version 3.0* | NIA | Not |
Schuette et al., 2012 [29] | Lung cancer (NSCLC) | 95 (F = 29, M = 66) Mean age (SD) = Placebo group: 64.2y (± 7.7), Treatment group: 61.6y (± 9.8) | Grade ≥ 2 dysphagia = Palifermin group: 30 subjects (61%), Placebo group: 32 subjects (70%) Grade ≥ 3 dysphagia = Palifermin group: 11 subjects (22%), Placebo group: 13 subjects (28%) Grade 4 dysphagia = reported for one subject in the palifermin group | Twice weekly: CTCAE version 3.0* | Median = Placebo: 319 days, Palifermin: 513 days | Not |